University of California, Davis
Iquitos, Peru
NCT Number: NCT03553277
Dengue viruses are the most medically important arthropod-borne pathogens worldwide, with transmission occurring in most tropical and sub-tropical regions. An estimated 390 million infections occur yearly. Although, there are considerable ongoing efforts to develop a vaccine, vector control remains the only option for reducing dengue virus (DENV) transmission and disease burden. The recent emergence of Aedes-borne Zika (ZIKV) and Chikungunya viruses (CHIKV) highlight need for novel vector control tools. The goal of this project is to determine the efficacy of a spatial repellent (SR) product (active ingredient transfluthrin) for reducing contact between household residents and vector mosquitos and as a result reduce DENV, ZIKV, and/or other Aedes-borne virus transmission. Henceforth the investigators will designate the combined risk of Aedes-borne dengue, Chikungunya, Zika virus transmission by (DCZV). Spatial repellency is used here as a general term to refer to a range of insect behaviors caused by airborne chemicals that reduce contact between people and disease vectors. This can include movement away from a chemical stimulus, and interference with host detection (attraction-inhibition) and/or feeding response.
Looking for future studies?
Notify Me2 year and older
All sexes
Interventional
Not applicable
Iquitos, Peru
Protection provided by this product will be measured using entomological and virological approaches, comparing entomological indices will be measured through standard household monitoring of Aedes aegypti population densities, while DCZV transmission will be measured through door-to-door surveillance for active dengue disease and through serological monitoring for DCZV exposure in a randomized cluster trial.
The investigators will establish a cohort of 3,400 persons, primarily children 2-12 years of age and adults who have not been previously infected with DCZV who will provide annual blood samples when they are healthy (longitudinal cohort), whereas in the same clusters the investigators expect to monitor up to 27,500 residents for active dengue disease (febrile surveillance cohort). The cohort will be monitored for a period of 2 years. The use of spatial repellents has never been tested on a large scale to reduce disease and could change vector control practices worldwide, reducing the amount of chemical insecticides applied and also prevent the development of insecticide resistance. The investigators plan to implement a short questionnaire to determine levels of acceptability and perceived efficacy amongst participating households.
The project will be carried out in the Amazonia City of Iquitos, Peru, which has a well-established infrastructure for studying urban dengue fever. The study will generate rigorous evidence, documenting and evaluating the impact of SR products on human infection rates, to be considered and used by academia, industry and public health key stakeholders at the global, regional, national and/or local level and drive efforts to acquire full recommendation of SR products for inclusion in disease control programs.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
LONGITUDINAL SEROCONVERSION Individual Level
Inclusion criteria
Exclusion criteria
FEBRILE SURVEILLANCE Household Level
Inclusion criteria
Exclusion criteria
FEBRILE SURVEILLANCE Individual Level
Inclusion criteria
Exclusion criteria
ENTOMOLOGICAL MONITORING Household Level
Inclusion criteria
Exclusion criteria
SPATIAL REPELLENT INTERVENTION Household Level
Inclusion criteria
Exclusion criteria
passive emanator with formulated transfluthrin
passive emanator with formulated inert ingredients
Time frame: 2 years
Compare laboratory confirmed Aedes-borne dengue, Zika virus seroconversion rates in subjects residing in households with active and placebo product, receiving standard entomological surveillance and control procedures by the local ministry of health, as an indicator for ABV infections.
Time frame: 2 years
Compare laboratory confirmed Aedes-borne dengue, Zika virus infection rates in subjects residing in households with active and placebo product, receiving standard entomological surveillance and control procedures by the local ministry of health, as an indicator for ABV disease.
Time frame: 2 years
Compare adult female Aedes aegypti indoor abundance in households with active and placebo product as an indicator for reduced mosquito house entry due to effect of product.
Time frame: 2 years
Compare adult female Aedes aegypti blood fed abundance in households with active and placebo product as an indicator for reduced mosquito human contact due to effect of product.
Time frame: 2 years
Compare adult female Aedes aegypti parity rates in households with active and placebo product as an indicator for reduced mosquito survival due to effect of product.
Time frame: 2 years
Compare perceived efficacy of the product to reduce mosquito nuisance in households with active and placebo product as an indicator for product acceptability.
University of Notre Dame
Other
Spatial Repellent Products for Control of Vector-borne Diseases - Dengue
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05452447
Alphavirus Infections, Arbovirus Infections
Colombo, West, Sri Lanka
View Trial DetailsNCT06268691
Alphavirus Infections, Arbovirus Infections
Cúcuta, Norte de Santander Department, Colombia
View Trial DetailsNCT06651372
Alphavirus Infections, Arbovirus Infections
Strasbourg, France
View Trial DetailsNCT06599970
Arbovirus Infections, Behavior
Havana, La Habana, Cuba
View Trial Details